Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol + tibolone is a hypothetical or investigational combination of two hormonal agents used in the management of menopausal symptoms. Estradiol is a natural estrogen hormone, while tibolone is a synthetic steroid with estrogenic, progestogenic, and androgenic activity. Both are used individually for hormone replacement therapy (HRT) in postmenopausal women to alleviate vasomotor symptoms (such as hot flushes), improve mood and sexual function, and prevent osteoporosis. Tibolone acts as an agonist at estrogen receptors (with preference for ER alpha), progesterone receptors, and androgen receptors through its active metabolites. While both drugs are established HRT options on their own, there is no evidence that they are marketed or clinically used together as a fixed-dose combination; rather, they may be compared head-to-head or against other HRT regimens in clinical studies[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + tibolone.